According to the Cleveland Clinic, Aspergillosis is an infection or allergic reaction caused by various kinds of molds found on plants, soil, building materials or rotting vegetables. Aspergillosis treatment market can be segmented on the basis of several types such as allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis and cutaneous (skin) aspergillosis. ABPA is observed as one of the most common aspergillosis in which inflammation in the lungs and allergy symptoms such as coughing and wheezing are observed. ABPA is treated with delivery of steroids such as prednisolone through aerosol during the attacks; in some cases itraconazole is also used to reduce the dose of steroids. ABPA usually affects people suffering with asthma and cystic fibrosis around 1 in every 40 people in asthma may be affected by ABPA. Invasive aspergillosis is the most severe type of aspergillosis as the infection travels from lung to bloodstream infecting other organs such as kidneys, liver, skin or brain; mostly observed in people with low immunity. Invasive aspergillosis is treated with voriconazole, caspofungin, micafungin, itraconazole, amphotericin B, or posaconazole. Medical practitioners suggest that prophylactic antifungal therapy accompanied by use of laminar airflow (LAF) or high-efficiency particulate air (HEPA) filtration in patient rooms can prevent risk of aspergillosis especially in patients who receive organ transplants.
The recent FDA approval received by isavuconazole (Cresemba) for invasive aspergillosis in March 2015 is considered as the major boost to the aspergillosis treatment market in the near future. Approval was based on the SECURE study (n = 516) that demonstrated isavuconazole as non-inferior voriconazole on the primary endpoint of all-cause mortality at day 42 for the treatment of adult patients with invasive aspergillosis or other filamentous fungi (isavuconazole 18.6% vs voriconazole 20.2%). The report also suggested that, isavuconazole has activity against most strains of the following microorganisms, both in vitro and in clinical infection: Aspergillus niger, Aspergillus fumigatus, and Aspergillus flavus.
Aspergillosis treatment market can be segmented on the basis of drug class such as antifungal and corticosteroids. Antifungals can be further classified as voriconazole, itraconazole, caspofungin, micafungin, amphotericin B, and isavuconazole. Corticosteroids that highly preferred in aspergillosis treatment are prednisolone, prednisone and methylprednisolone. The prevalence of aspergillosis is about 1-2 in 100,000 people every year.
The global aspergillosis treatment market is segmented on the following bases:
Key Players Identified for Aspergillosis Treatment Market Include but are Not Limited to:
The key players in the market are Pfizer Inc., Astra Zeneca plc, Merck & Co., GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott Laboratories, Inc., Takeda Pharmaceutical Company Ltd., Janssen Global Services, LLC (Subsidiary of Johnson & Johnson Services, Inc.), Basilea Pharmaceutica Ltd., and others.
This report offers: